Headache & Migraine
Video
Maria Eduarda Nobre, MD, PhD
Dr. Alan Rapoport interviews Dr. Maria Eduarda Nobre about clomiphene treatment for refractory episodic and chronic cluster headache.
Video
Alan Rapoport, MD
At the American Headache Society’s 60th Annual Scientific Meeting, Dr. Alan Rapoport summarizes a poster he presented regarding ZOTRIP, Zosano...
Commentary
25+ Years of Migraine
Although migraine has been with humans since...
Conference Coverage
Fremanezumab May Be an Effective Preventive Treatment for Chronic Migraine
LOS ANGELES—Fremanezumab, a fully humanized monoclonal antibody, is a safe and effective therapy for the preventive treatment of...
Conference Coverage
Eptinezumab May Reduce Migraine Frequency in Patients With Chronic and Episodic Migraine
LOS ANGELES—Among patients with chronic migraine, IV infusion of eptinezumab significantly reduces the average number of migraine...
Conference Coverage
Ubrogepant May Treat Acute Migraine Attacks Effectively
LOS ANGELES—Ubrogepant may relieve the pain of acute migraine attacks, as well as other bothersome migraine-related symptoms, according to data...
Conference Coverage
How Common Are Comorbidities in Chronic Versus Episodic Migraine?
LOS ANGELES—Significantly more patients with chronic migraine versus episodic migraine report cardiovascular, respiratory, gastrointestinal,...
Conference Coverage
Erenumab May Control Migraines When Other Preventives Have Failed
LOS ANGELES—Patients who have tried and failed other preventive therapies may find that erenumab can prevent their migraines, according to a study...
Conference Coverage
Noninvasive Neurostimulator Shows Efficacy in Episodic Migraine
LOS ANGELES—Noninvasive vagus nerve stimulation (nVNS) is a rapidly effective, well-tolerated, and practical option for the acute treatment of...
News
FDA Updates
The FDA approved Aimovig (erenumab-aooe) for the preventive treatment of migraine in adults. Aimovig is the first FDA-approved preventive migraine...
FDA/CDC
FDA approves Aimovig for migraine prevention
Aimovig is the first FDA-approved treatment to prevent migraines by blocking the calcitonin gene–related peptide receptor.